A compound having Formula: or a stereoisomer, a tautomer, an N-oxide, a solvate, or a pharmaceutically acceptable salt thereof, wherein: Z is or a stereoisomer thereof, wherein each X is independently NH or O, each X' is independently CH 2 or NH; and wherein Z is optionally substituted by 1, 2 or 3 R 2 groups; Z 1 is H or C 1 -C 12 alkyl, wherein Z 1 is optionally substituted by 1, 2, 3, 4 or 5 R 3 groups; A is pyrazolyl or imidazolyl, wherein A is optionally substituted by 1, 2, 3, 4 or 5 R 4 groups; R 1 is H, F, Cl, Br, I, NO 2, N 3, CN, C 1 -C 12 alkyl, C 1 -C 12 haloalkyl, C 1 -C 12 alkoxyl or -C(=O)R 5, wherein R 1 is optionally substituted by 1, 2, 3, 4 or 5 R 8 groups; each R 2 is independently H, -C(=O)CH 2 CN, C 1 -C 12 alkyl, C 1 -C 12 haloalkyl, 5-12 membered heteroaryl, -C(=O)R 5 or -S(=O) 2 R 5, wherein each of the above substituents is optionally independently substituted by 1, 2, 3, 4 or 5 R 8 groups; each R 3 and R 4 is independently H, F, Cl, Br, I, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl or C 3 -C 12 cycloalkyl; each R 5 is independently H, C 1 -C 12 alkyl or C 2 -C 12 alkenyl, wherein each R 5 is optionally independently substituted by 1, 2, 3, 4 or 5 R 8 groups; each R 8 is independently F, Cl, Br, I, CN, NO 2, N 3, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 3 -C 12 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heterocyclyl, 5-12 membered heteroaryl, NH 2, - NH(C 1 -C 12 alkyl), -NH(CH 2) n -(C 3 -C 12 cycloalkyl), -NH(CH 2) n -(C 6 -C 12 aryl), -NH(CH 2) n -(3-12 membered heterocyclyl), -NH(CH 2) n -(5-12 membered heteroaryl), -N(C 1 -C 12 alkyl) 2, -N[(CH 2) n -(C 3 -C 12 cycloalkyl)] 2, -N[(CH 2) n -(C6-C 12 aryl)] 2, -N[(CH 2) n -(3-12 membered heterocyclyl)] 2, -N[(CH 2) n -(5-12 membered heteroaryl)] 2, OH, -O(C 1 -C 12 alkyl), -O(CH 2) n -(C 3 -C 12 cycloalkyl), -O(CH 2) n -(C 6 -C 12 aryl), -O(CH 2) n -(3-12 membered heterocyclyl) or -O(CH 2) n -(5-12 membered heteroaryl); each m is independently 1 or 2; and each n is independently 0, 1, 2, 3 or 4. Z is or a stereoisomer thereof, wherein each X is independently NH or O, each X' is independently CH 2 or NH; and wherein Z is optionally substituted by 1, 2 or 3 R 2 groups; Z 1 is H or C 1 -C 12 alkyl, wherein Z 1 is optionally substituted by 1, 2, 3, 4 or 5 R 3 groups; A is pyrazolyl or imidazolyl, wherein A is optionally substituted by 1, 2, 3, 4 or 5 R 4 groups; R 1 is H, F, Cl, Br, I, NO 2, N 3, CN, C 1 -C 12 alkyl, C 1 -C 12 haloalkyl, C 1 -C 12 alkoxyl or -C(=O)R 5, wherein R 1 is optionally substituted by 1, 2, 3, 4 or 5 R 8 groups; each R 2 is independently H, -C(=O)CH 2 CN, C 1 -C 12 alkyl, C 1 -C 12 haloalkyl, 5-12 membered heteroaryl, -C(=O)R 5 or -S(=O) 2 R 5, wherein each of the above substituents is optionally independently substituted by 1, 2, 3, 4 or 5 R 8 groups; each R 3 and R 4 is independently H, F, Cl, Br, I, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl or C 3 -C 12 cycloalkyl; each R 5 is independently H, C 1 -C 12 alkyl or C 2 -C 12 alkenyl, wherein each R 5 is optionally independently substituted by 1, 2, 3, 4 or 5 R 8 groups; each R 8 is independently F, Cl, Br, I, CN, NO 2, N 3, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 3 -C 12 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heterocyclyl, 5-12 membered heteroaryl, NH 2, - NH(C 1 -C 12 alkyl), -NH(CH 2) n -(C 3 -C 12 cycloalkyl), -NH(CH 2) n -(C 6 -C 12 aryl), -NH(CH 2) n -(3-12 membered heterocyclyl), -NH(CH 2) n -(5-12 membered heteroaryl), -N(C 1 -C 12 alkyl) 2, -N[(CH 2) n -(C 3 -C 12 cycloalkyl)] 2, -N[(CH 2) n -(C6-C 12 aryl)] 2, -N[(CH 2) n -(3-12 membered heterocyclyl)] 2, -N[(CH 2) n -(5-12 membered heteroaryl)] 2, OH, -O(C 1 -C 12 alkyl), -O(CH 2) n -(C 3 -C 12 cycloalkyl), -O(CH 2) n -(C 6 -C 12 aryl), -O(CH 2) n -(3-12 membered heterocyclyl) or -O(CH 2) n -(5-12 membered heteroaryl); each m is independently 1 or 2; and each n is independently 0, 1, 2, 3 or 4.